Brazil is not Latin America, and treating it that way costs you the rest

Across much of Latin America, hospital purchasing runs through published tender processes. That is unusually good news for anyone evaluating the region, because a tender history is a far better demand signal than any market-size estimate: it tells you what was actually bought, often by whom, at what value, and in the specification language buyers really use.

Brazil's procurement trail is the deepest in the region and among the most useful anywhere. If you are weighing Latin America and have not looked at who has been winning public contracts in your category, you are guessing at a question that has a published answer.

Costa Rica's register is far larger than its population would suggest — comparable in size to markets many times larger. That is because it is a significant medical device manufacturing and export hub, not because it is a large domestic market.

It is a useful illustration of why record counts should never be read as market size. The number tells you something real and important about Costa Rica; it just is not the thing most people assume it is. Nearly two-thirds of its registered manufacturers also hold a US or EU registration, which is the signature of an export-oriented base rather than a domestic one.

Brazil dominates the region by volume and sets the tone: local holder, real translation burden, and a timeline that rewards preparing the dossier properly rather than filing early. The smaller markets are frequently entered on the back of an approval already held elsewhere.

Attribution is thinner here than the record counts suggest — a large share of Mexican records name no manufacturer at all, so any ranking of "who is present" understates the field rather than describing it.